Small molecule · developed by Kiora Pharmaceuticals
KIO-301 is an ophthalmic intravitreal formulation of the quaternary ammonium chloride salt KIO-300-Cl, whose active compound is KIO-300, in sulfobutylether-β-cyclodextrin, sucrose and phosphate buffer. It is studied in inherited retinal diseases, including retinitis pigmentosa and choroideremia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06628947 | Phase 2 | Retinitis Pigmentosa | Recruiting | KPRX |
| NCT05282953 | Phase 1/2 | Retinitis Pigmentosa | Completed | KPRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal DiseasesRetinitis Pigmentosa
Updated Oct 18, 2026. Something wrong or missing? Report it on the KPRX page.
See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KPRX catalysts and pipeline →